The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co. Inc.’s (NYSE:MRK) Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in ...
Positive opinion granted for SC administration of KEYTRUDA for all adult indications approved in the European Union for KEYTRUDA Positive opinion also granted for KEYTRUDA as part of a perioperative ...
The FDA has approved Merck & Co.’s under-the-skin version of Keytruda, reducing treatment time burden for patients while granting the world’s bestselling drug potential blockbuster revenue protection.
KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute ...
RAHWAY, N.J. - The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted two positive opinions for Merck’s (NYSE:MRK) anti-PD-1 therapy KEYTRUDA, the company ...
Panelists discuss how the IMscin001 trial findings established subcutaneous atezolizumab noninferiority with comparable efficacy and safety to intravenous (IV) formulation while highlighting ...
AstraZeneca announced that the Phase III TULIP-SC trial of SAPHNELO (anifrolumab) for treatment of people with systemic lupus erythematosus met its primary endpoint. Trial results showed that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback